We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Alpha-Thalassemia Affects HbA1c Measurement

By LabMedica International staff writers
Posted on 01 Jun 2016
A major glycated hemoglobin, known as HbA1c, is characterized by non-enzymatic binding of glucose to the N-terminal valine residue of the hemoglobin b-chain, is a widely used biomarker in the management of diabetes.

α-Thalassemia is a benign condition that is seen some in patients with diabetes mellitus and is due to impaired production of alpha chains from 1,2,3, or all 4 of the alpha globin genes, leading to a relative excess of beta globin chains. More...
The degree of impairment is based on which clinical phenotype is present.

Clinical medical scientists at the Peking University Shenzhen Hospital (Guangdong, China) tested a total of 189 EDTA whole blood samples from all patients for complete blood counts with red cell indices and HbA2 using an XN9000 analyzer (Sysmex Corporation, Kobe, Japan) and hemoglobin capillary electrophoresis (Sebia Benelux, Vilvoorde, Belgium). Samples were separated into several aliquots and frozen at -80 °C before HbA1c analysis.

Plasma samples were tested for fasting glucose (FG), albumin, fructosamine, and ferritin immediately after centrifugation. The effects of the number of functionalα-genes on HbA1c measurement was investigated by boronate affinity high-performance liquid chromatography (HPLC; Ultra²; Trinity Biotech, Kansas City, MO, USA).

In patients with two or three functional α-genes, HbA1c values were not significantly different from those of controls; however, in individuals with α-thalassemia with one functional α-gene (i.e., HbH disease), HbA1c levels were significantly different from those of controls. HbA1c values were significantly lower in individuals with HbH disease than in control individuals and patients in the other two α-thalassemia groups. For patients with HbH disease, there were no significant differences in the four HbA1c measurement systems.

The authors concluded that HbA1c values in samples from individuals with two or three functional α-genes basically reflected the normal mean blood glucose level, while those in samples from individuals with one functional α-gene did not. Therefore for patients with HbH disease, HbA1c values cannot be used for the assessment of diabetes because HbA1c values do not reflect the mean blood glucose level. The study was published on May 17, 2016, in the Journal of Clinical Laboratory Analysis.

Related Links:
Peking University Shenzhen Hospital
Sysmex
Sebia Benelux
Trinity Biotech

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.